GSK (NYSE:GSK) Receives “Buy” Rating from Jefferies Financial Group

Jefferies Financial Group restated their buy rating on shares of GSK (NYSE:GSK) in a research report report published on Monday morning,Benzinga reports.

Several other equities research analysts have also weighed in on GSK. Wall Street Zen raised GSK from a “buy” rating to a “strong-buy” rating in a report on Friday, September 5th. Weiss Ratings reissued a “hold (c)” rating on shares of GSK in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, GSK presently has an average rating of “Hold” and an average price target of $37.38.

GSK Trading Up 1.5%

NYSE GSK opened at $43.88 on Monday. The stock has a market capitalization of $89.19 billion, a price-to-earnings ratio of 20.31, a PEG ratio of 1.95 and a beta of 0.53. GSK has a one year low of $31.72 and a one year high of $46.87. The company has a debt-to-equity ratio of 1.07, a current ratio of 0.87 and a quick ratio of 0.57. The business’s fifty day moving average is $41.62 and its 200-day moving average is $39.44.

GSK (NYSE:GSK) last announced its quarterly earnings data on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share for the quarter, topping the consensus estimate of $1.12 by $0.11. GSK had a return on equity of 49.22% and a net margin of 10.81%.The company had revenue of $10.64 billion during the quarter, compared to analyst estimates of $7.92 billion. During the same quarter last year, the firm posted $0.43 EPS. The firm’s revenue for the quarter was up 1.3% on a year-over-year basis. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. Equities research analysts predict that GSK will post 4.14 EPS for the current year.

GSK Cuts Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, October 9th. Stockholders of record on Friday, August 15th were issued a dividend of $0.4206 per share. The ex-dividend date of this dividend was Friday, August 15th. This represents a $1.68 annualized dividend and a dividend yield of 3.8%. GSK’s payout ratio is presently 78.24%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Twin Peaks Wealth Advisors LLC purchased a new position in shares of GSK during the second quarter worth about $25,000. HHM Wealth Advisors LLC grew its holdings in shares of GSK by 222.2% during the first quarter. HHM Wealth Advisors LLC now owns 667 shares of the pharmaceutical company’s stock worth $26,000 after purchasing an additional 460 shares in the last quarter. Costello Asset Management INC purchased a new position in shares of GSK during the first quarter worth about $31,000. SOA Wealth Advisors LLC. grew its holdings in shares of GSK by 252.1% during the second quarter. SOA Wealth Advisors LLC. now owns 845 shares of the pharmaceutical company’s stock worth $32,000 after purchasing an additional 605 shares in the last quarter. Finally, Richardson Financial Services Inc. grew its holdings in shares of GSK by 127.9% during the first quarter. Richardson Financial Services Inc. now owns 841 shares of the pharmaceutical company’s stock worth $33,000 after purchasing an additional 472 shares in the last quarter. Hedge funds and other institutional investors own 15.74% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.